Sarepta Therapeutics, Inc. (SRPT) stock price, news, quote and history
This article provides a comprehensive overview of Sarepta Therapeutics, Inc. (SRPT), including its current stock price, recent performance data, and key financial metrics. It details the company's focus on developing RNA-targeted therapeutics and gene therapies for rare diseases like Duchenne muscular dystrophy, listing its main commercial products and pipeline. The report also includes analyst ratings, earnings trends, and valuation measures for the biotechnology company.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 30, 2026
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards consisting of 211,070 restricted stock units (RSUs) to 37 new employees hired in the third quarter of 2026. These inducement grants, approved by the Compensation Committee and in accordance with Nasdaq Listing Rule 5635(c)(4), will vest over four years. This initiative aims to attract and retain talent in the company's mission to develop precision genetic medicines for rare diseases.
Equity in earnings of Sarepta Therapeutics, Inc. – HAN:AB3A
This article provides financial information for Sarepta Therapeutics, Inc. (HAN:AB3A) as listed on the Hannover Stock Exchange through TradingView. It specifically highlights the "Equity in earnings" for the company, indicating the value and change during a particular period. The content primarily serves as a data display for the stock's financial performance.
Sarepta Therapeutics stock falls 1.28 percent as DMD data land
Sarepta Therapeutics' stock dropped 1.28% after new clinical data for ELEVIDYS was presented at the World Muscle Society congress, showing sustained functional improvements in older Duchenne muscular dystrophy patients, but also highlighting safety concerns with a boxed warning for liver injury. The company's Q2 2026 revenue exceeded estimates but was down year-over-year, leading to a mixed financial outlook. The data's impact on expanding the commercial value of ELEVIDYS across a wider patient population is crucial for the stock's future.
Sarepta presents Elevidys data in older Duchenne patients
Sarepta Therapeutics presented new data on its gene therapy, Elevidys, for Duchenne muscular dystrophy patients aged 8 to 12, showing functional improvements over two years compared to control groups. The company also reported dystrophin expression levels in younger patients aged 2-3. The safety profile was consistent with previous observations, with nausea and vomiting being common side effects, and the therapy carries a boxed warning for liver injury.
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics presented new data at the 2026 World Muscle Society Annual Congress, highlighting the safety and efficacy of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory Duchenne muscular dystrophy patients aged 8-12. The data showed durable and clinically meaningful functional benefits over two years compared to a control group. Additionally, an analysis of patients aged 2 to under 3 demonstrated robust micro-dystrophin expression and sarcolemmal localization, expanding the evidence base across different age groups.
Operating cash flow per share of Sarepta Therapeutics, Inc. – HAN:AB3A
This article provides financial information for Sarepta Therapeutics, Inc. (HAN:AB3A) on the TradingView platform, specifically focusing on its operating cash flow per share. It appears to be a data point within a larger financial overview for the company.
SRPT Reiterates by Needham -- Maintains Underperform Rating
Needham analyst Gil Blum has reiterated an "Underperform" rating for Sarepta Therapeutics (SRPT), reflecting ongoing caution despite the stock being significantly undervalued according to GF Value™. The company, which specializes in precision genetic medicine, shows moderate overall performance with strengths in growth and momentum but weaknesses in profitability and valuation. While 6 gurus hold SRPT and 5 have increased positions, investors are advised to exercise caution due to the high Price-to-Sales ratio and current unprofitability.
Sarepta Therapeutics, Inc. Revenue Breakdown – LS:A1J1BH
Sarepta Therapeutics, Inc. (A1J1BH) generated 1.87 billion EUR in total revenue last year, with its RNA-targeted Therapeutics segment contributing the most at 1.59 billion EUR. The United States was the primary regional contributor, accounting for 1.45 billion EUR of the company's revenue. These figures represent a slight decrease from the previous year's performance.
SRPT Should I Buy
Sarepta Therapeutics (SRPT) is currently trading below analyst price targets, suggesting potential upside, but is considered oversold with negative momentum and significant hedge fund selling. Despite some positive catalysts like an upcoming presentation and shifting retail investor sentiment, financial performance shows declining revenue and lower gross margins. Analysts have mixed ratings, with some maintaining Outperform/Buy based on differentiation from competitors, while others suggest a Sell.
Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn
Sarepta Therapeutics' stock dropped 7.2% despite settling a patent infringement lawsuit with REGENXBIO and the University of Pennsylvania regarding ELEVIDYS and AAVrh74-based gene therapies. The settlement, involving a US$39.0 million payment, provides Sarepta with freedom to operate but shifts investor focus back to ELEVIDYS's clinical performance, safety, and commercial execution. Analysts offer varying forecasts for Sarepta's future revenue and earnings, with some predicting a significant upside while others remain cautious due to reliance on ELEVIDYS.
Sarepta Therapeutics (SRPT) Falls As Patent Settlement Tests The Undervalued Narrative
Sarepta Therapeutics (SRPT) experienced a 7.1% share price drop following a sector-wide biotech selloff and a major patent litigation settlement, pushing its stock to $18.39. Despite a 90-day return of 9.14%, the stock is down 11.03% over the past week. Analysts currently value SRPT at $21.65, suggesting it is 15% undervalued, but its future depends on pipeline development and resolution of gene therapy safety concerns and administrative delays.
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sarepta Therapeutics will present new data on its Duchenne muscular dystrophy treatments at the 31st Annual Congress of the World Muscle Society from September 29 to October 3, 2026, in Hiroshima, Japan. Presentations will include efficacy and safety outcomes of delandistrogene moxeparvovec in various age groups and a pooled safety analysis, as well as efficacy and safety data for golodirsen and casimersen. The company also provides important safety information for ELEVIDYS (delandistrogene moxeparvovec-rokl), including boxed warnings about acute serious liver injury and contraindications.
Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential
Jefferies has reiterated a Buy rating and a $30.00 price target for Sarepta Therapeutics (NASDAQ: SRPT), citing significant pipeline potential from its siRNA platform. The firm anticipates crucial data readouts in 2026 and 2027 for DM1, FSHD, DMD, and LGMD programs, each representing substantial market opportunities. Despite a recent earnings beat, the stock remains undervalued according to InvestingPro analysis, with the DMD franchise alone offering significant valuation support.
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Sarepta Therapeutics will present new data from its neuromuscular portfolio at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting. The presentations will include the first results from the Phase 4 ENDURE Study, evaluating delandistrogene moxeparvovec in Duchenne muscular dystrophy patients, including safety data with sirolimus. Sarepta aims to provide insights into real-world use and reinforce the understanding of the safety and effectiveness of their treatments for Duchenne and other neuromuscular diseases.
Sarepta Therapeutics Drops 7.1% Amid Sector-Wide Selling
Sarepta Therapeutics experienced a 7.1% drop in its stock price, closing at $19.33, as a broad selloff impacted the biotechnology sector. This decline was not due to company-specific news but rather a wider market trend, with several other biotech firms also reporting significant losses. Investors are advised to observe whether this sector-wide weakness will continue or stabilize.
Patent Settlement Clears Key Gene Therapy Risk For Sarepta Therapeutics Stock
Sarepta Therapeutics has settled a gene therapy patent dispute with REGENXBIO and the University of Pennsylvania for $39.0 million, resolving legal uncertainty around its AAVrh74-based gene therapies like ELEVIDYS. This settlement removes a significant legal risk, allowing the company to focus on the commercial uptake and clinical development of its pipeline, including ELEVIDYS, which analysts project will contribute to future revenue growth and a shift to profitability by 2029.
Sarepta Therapeutics (BOVESPA:S1RP34) - analisi del titolo
This article provides an analysis of Sarepta Therapeutics (BOVESPA:S1RP34), a biopharmaceutical company focused on developing therapies for rare diseases. It covers the company's financial overview, future growth predictions, past performance, and recent news, including FDA approvals, revenue guidance revisions, and clinical trial updates for its Duchenne muscular dystrophy treatments. The analysis highlights that the stock is trading significantly below its estimated fair value despite high volatility and expected earnings decrease.
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta tumbled after Novartis' treatment for myotonic dystrophy type 1 failed a trial, raising concerns for other drug developers in the tough-to-treat rare disease space. Dyne's stock dropped almost 18% due to the similarity of its trial's key goal with Novartis's failed approach, while Sarepta and PepGen also saw significant declines. Analysts expressed disappointment, highlighting the increased risk for companies pursuing therapies for myotonic dystrophy, a genetic disorder with no approved treatments.
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
Sarepta Therapeutics has announced the 25 recipients of its Route 79 Duchenne Scholarship Program for the 2026-2027 academic year, including 20 individuals living with Duchenne muscular dystrophy and five siblings. Now in its ninth year, the program provides up to $5,000 to each student to support their post-secondary education, recognizing their commitment and resilience. The scholarships are chosen by an independent committee based on academic record, community involvement, essays, and recommendations, and have supported over 150 students since inception.
Sarepta Therapeutics Faces Investor Investigations – 8-5
Sarepta Therapeutics (NASDAQ: SRPT) is under increased scrutiny from investors and law firms due to multiple ongoing investigations, securities litigation, and derivative lawsuits. Kahn Swick & Foti (KSF) is the latest firm to announce an investigation into potential breaches of fiduciary duties by Sarepta's officers and directors. The legal actions stem from regulatory and investor concerns regarding ELEVIDYS, Sarepta’s gene therapy for Duchenne muscular dystrophy, and other therapies utilizing the company's AAVrh74 platform, following patient deaths and substantial stock price decline.
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) concerning potential breaches of fiduciary duties by its officers and directors. The investigation stems from allegations that Sarepta repeatedly touted the safety of its Duchenne muscular dystrophy treatment, Elevidys, despite multiple patient deaths from acute liver failure, leading to a securities class action lawsuit. KSF is inviting long-term shareholders to come forward with information to assist their inquiry.
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) shares have risen 37% since its last earnings report, outperforming the S&P 500. The company reported better-than-expected Q2 2026 adjusted EPS and revenues, though overall revenues were down year-over-year due to lower Elevidys sales. Sarepta also narrowed its 2026 net product revenue guidance but raised its collaboration and other revenues forecast.
Sarepta Therapeutics (SRPT) Stock Looks Stretched On Sales Yet Reasonable On Broader Checks
Sarepta Therapeutics (SRPT) stock has experienced a significant decline of 84.7% over three years, leading to a mixed valuation picture. While its P/S ratio of 1.0x appears overvalued compared to its fundamentals (fair P/S of 0.8x), it is still well below the biotech industry average. The company's future hinges on the profitable growth of ELEVIDYS and its wider portfolio, balancing potential upside against regulatory and cost uncertainties.
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into Sarepta Therapeutics, Inc. (SRPT) concerning potential breaches of fiduciary duties by its officers and directors. The investigation follows multiple patient deaths from acute liver failure after treatment with Sarepta's Duchenne muscular dystrophy drug, Elevidys, and a subsequent securities class action lawsuit against the company. KSF is seeking information from long-term shareholders to determine if Sarepta's leadership violated state or federal laws.
Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally
Sarepta Therapeutics (SRPT) saw an 8.6% increase in its stock price, closing at $19.57 amidst a broad rally in the biotechnology sector. This surge was not driven by company-specific news but rather by a sector-wide advance that also saw gains in several peer companies, suggesting a general rotation of investor interest into biotech. Investors are advised to monitor whether this sector momentum is sustainable and to observe volume trends and any divergence between Sarepta and its peers in upcoming trading sessions.
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2% - Here's Why
Sarepta Therapeutics (NASDAQ:SRPT) shares increased by 9.2% in Wednesday trading, reaching $19.68, despite significantly lower trading volume. The company's recent quarterly results surpassed analyst expectations with an adjusted EPS of $0.64 and revenue of $401.25 million, though revenue was down 34.3% year-over-year. Analyst sentiment is mixed, with an average price target of $25.06, indicating potential upside.
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline
Sarepta Therapeutics reported strong Q2 2026 financial results, including $328.7 million in net product revenue and both GAAP and non-GAAP operating income, driven by PMO and ELEVIDYS sales. The company also announced the appointment of Michael Severino as its new CEO, who will lead Sarepta's continued advancement of its rare disease pipeline, with key data readouts for DM1 and FSHD expected in H2 2026 and a new Huntington's disease program initiated. Despite a year-over-year revenue decrease attributed to an updated ELEVIDYS label and a missed milestone payment, Sarepta narrowed its 2026 revenue guidance to $1.2 billion to $1.3 billion and ended Q2 with a robust cash position of approximately $945 million.
Sarepta Posts US$328.7M Results
Sarepta Therapeutics Inc. (SRPT:NASDAQ) reported Q2 2026 product revenue of US$328.7 million, driven by PMO and ELEVIDYS sales, and announced Michael Severino as its new CEO. The company narrowed its 2026 revenue guidance to US$1.2 billion to US$1.3 billion and expects important data readouts for its DM1 and FSHD programs in the second half of 2026. Despite a decrease in total revenue compared to Q2 2025 due to updated ELEVIDYS labeling and the absence of a milestone payment, Sarepta maintains a strong balance sheet and an active pipeline for rare diseases.
GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT
GSA Capital Partners LLP has acquired a new stake in Sarepta Therapeutics (NASDAQ:SRPT), purchasing 103,618 shares valued at approximately $1.86 million, representing 0.10% of the company. Other institutional investors have also adjusted their holdings in SRPT, with institutional ownership collectively standing at 86.68%. Despite the stock's opening at $18.10, analysts hold a mixed view with an average "Hold" rating and a consensus price target of $25.06.
Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?
Sarepta Therapeutics (SRPT) recently narrowed its 2026 revenue guidance to $1.2b to $1.3b, alongside positive second-quarter results and pipeline updates for rare disease programs. Despite a recent 7-day share price jump of 15.38%, the stock is still down 13.75% year-to-date and 83.87% over three years. Analysts currently peg Sarepta as 15.1% undervalued with a fair value of $21.65, but significant risks like safety concerns around ELEVIDYS and high R&D costs persist.
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research
Zacks Research has upgraded Sarepta Therapeutics (NASDAQ:SRPT) from a "strong sell" to a "hold" rating, contributing to a mixed analyst sentiment that results in an overall "Hold" consensus with a $25.06 price target. The company's shares opened at $18.42, with a market cap of $1.95 billion, and institutional investors hold a significant 86.68% stake. Several other analysts have adjusted their ratings and price targets, reflecting ongoing evaluation of the biopharmaceutical company focused on genetic medicines for rare neuromuscular diseases.
Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value
Sarepta Therapeutics, Inc. has filed a Form 13F as an institutional investment manager, detailing one information table entry with an aggregate reported value of $0. The filing, signed by Executive Vice President and CFO Ryan Wong, indicates no other included managers. This quarterly report provides a look into the company's reportable holdings, which in this instance amount to zero value.
Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?
Sarepta Therapeutics recently tightened its 2026 revenue guidance to $1.2 billion to $1.3 billion and announced second-quarter results and pipeline updates. Despite a 15.38% share price jump over the last 7 days, the stock is down 13.75% year-to-date and 83.87% over three years. Analysts suggest a fair value of $21.65, indicating the stock is currently undervalued, but note ongoing safety concerns and high research costs as risks.
Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 5,329,691 shares, or 5.05%, of Sarepta Therapeutics, Inc. common stock as of June 30, 2026. This reported amount includes 1,004,002 shares represented by Convertible Notes. Both entities share voting and dispositive power over a significant portion of these shares, with no sole voting or dispositive power.
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom
Sarepta Therapeutics (SRPT) saw its flagship gene therapy, ELEVIDYS, experience a fifth consecutive quarterly revenue decline, with analysts from H.C. Wainwright & Co. reiterating a Sell rating and a $5.00 price target. Despite this, the market reaction was muted, suggesting investors are assigning significant value to the company's early-stage programs for myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), data for which are expected in the second half of 2026. The company's PMO franchise for Duchenne muscular dystrophy is stabilizing but faces future competitive pressure, and its cash position improved significantly in Q2 2026.
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT
Bank of America Corp DE significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 26.6% in the first quarter, now owning over 2.15 million shares valued at approximately $46.7 million. This move is part of a broader trend of institutional investors, including several hedge funds, increasing their positions in the biotechnology company, with overall institutional ownership at 86.68%. Despite mixed analyst ratings, the consensus remains a "Hold" with a target price of $25.06, while the stock currently trades around $18.38.
Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT
Assenagon Asset Management S.A. has initiated a new $8.16 million investment in Sarepta Therapeutics (NASDAQ:SRPT), acquiring 454,375 shares, which represents approximately 0.43% of the company. Institutional investors and hedge funds collectively own about 86.68% of SRPT. Despite mixed analyst ratings, with a consensus "Hold" and a target price of $25.06, the stock has recently traded between $14.68 and $25.32.
Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT
Dimensional Fund Advisors LP significantly reduced its stake in Sarepta Therapeutics, Inc. by selling 121,412 shares, leaving them with 336,736 shares valued at $7.3 million. Despite institutional investors owning a large portion of the company and some increasing their positions, analyst sentiment is mixed, resulting in a consensus "Hold" rating with an average price target of $25.06, against the stock's opening price of $17.18. Sarepta Therapeutics is a biopharmaceutical company focused on genetic medicines for rare neuromuscular diseases, particularly Duchenne muscular dystrophy.
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside
Sarepta Therapeutics (SRPT) is a biotechnology firm focusing on RNA-targeted therapeutics and gene therapies for rare diseases like Duchenne muscular dystrophy, with a market capitalization of $1.77 billion. Despite a revenue decline of 34.30% and negative EPS, analysts project a 31.63% potential upside, driven by its innovative pipeline including EXONDYS 51, VYONDYS 53, AMONDYS 45, and gene therapies. Investors are weighing the significant growth potential against financial challenges and inherent biotech risks.
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO
Sarepta Therapeutics' stock rose 12.9% despite cutting its 2026 revenue guidance and reporting weaker Q2 2026 results. The company appointed Michael Severino, M.D., as its new CEO, a move seen as a positive development due to his extensive biopharma background. The investment narrative now focuses on gene therapy execution, pipeline diversification, and managing safety concerns around its ELEVIDYS treatment.
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO
Sarepta Therapeutics' stock rose 12.9% despite cutting its 2026 revenue guidance to US$1.20 billion–US$1.30 billion and reporting lower Q2 2026 revenue of US$401.25 million, alongside a net loss. The company appointed Michael Severino, M.D., as the new CEO, a move seen as a positive leadership change, and filed a US$39.73 million employee stock offering. The article suggests investors are weighing the impact of new leadership and pipeline diversification against current financial setbacks and safety concerns surrounding its gene therapy, ELEVIDYS.
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics reported its second quarter 2026 financial results, with total net product revenues of $328.7 million and GAAP operating income of $13.3 million. The company announced the appointment of Michael Severino, MD, as the new CEO, who emphasized continued execution of commercial strategy, advancement of the siRNA pipeline, and disciplined capital allocation. Sarepta also narrowed its full-year 2026 revenue guidance to $1.2-$1.3 billion and provided updates on its clinical pipeline, including readouts for DM1 and FSHD, and progress in its Huntington’s disease program.
Price to earnings forward of Sarepta Therapeutics, Inc. – BX:AB3A
This article provides financial data for Sarepta Therapeutics, Inc. under the ticker BX:AB3A on the BX Swiss exchange. It specifically highlights the "Price to earnings forward" metric for the company. The page appears to be a financial data snippet from TradingView, focusing on market data provided by ICE Data Services and FactSet.
Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A
Sarepta Therapeutics, Inc. (BX:AB3A) generated 1.74 billion CHF in revenue last year, primarily from its RNA-targeted Therapeutics, Small Interfering RNA Platform, Gene Therapy, and Other Genetic Therapeutic Modalities segment, which contributed 1.48 billion CHF. The United States was the largest regional contributor, accounting for 1.35 billion CHF of the total revenue.
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer
Sarepta Therapeutics (SRPT) has appointed Michael Severino as its new Chief Executive Officer, bringing in a physician executive with extensive experience from major pharmaceutical companies. This leadership change occurs as Sarepta faces declining Q2 2026 revenues and has narrowed its full-year revenue guidance. Severino's focus will be on gene therapy execution, ELEVIDYS safety management, and balancing pipeline investment with cost control, with his initial impact expected to be evident in the Q3 2026 earnings report.
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer
Sarepta Therapeutics has appointed Michael Severino as its new Chief Executive Officer and a member of its Board of Directors. Severino, with a strong background in senior leadership and research in biotech, joins the company as it navigates a revenue reset, with Q2 2026 revenue down and narrowed 2026 guidance. Investors will be closely watching Severino's approach to gene therapy execution, ELEVIDYS safety management, and resource allocation across various programs, with his first full quarter as CEO serving as a key indicator of his strategy.
State Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G
State Street Corporation and its affiliate SSGA Funds Management, Inc. have reported a significant beneficial ownership stake in Sarepta Therapeutics (SRPT) through a Schedule 13G filing. State Street and related entities beneficially own 8.4% of Sarepta's common stock, totaling 8,916,103 shares, with shared voting power over 8,642,126 shares. Separately, SSGA Funds Management, Inc. holds a 6% beneficial ownership, comprising 6,285,547 shares.
Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop
Sarepta Therapeutics (SRPT) shares rose 5% after its Q2 2026 earnings report, despite a significant revenue drop, due to the company reporting positive GAAP operating income and tightening its full-year guidance. Investors see this as confirmation of the company's path to profitability, transitioning from a single-product focus to a broader Duchenne-funding base. However, bears highlight ongoing concerns regarding capacity, safety events, and timing risks for ELEVIDYS, which could hinder revenue growth in the short term.
Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT
Empowered Funds LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 1,898,816.7% in Q1, holding 113,935 shares valued at $2.48 million. Other institutional investors also adjusted their positions, and collective institutional ownership stands at 86.68%. Despite the company beating Q2 earnings and revenue estimates, its revenue declined 34.3% year-over-year, leading to mixed analyst ratings and a consensus "Hold" with an average price target of $24.72.
